Increased prevalence of pediatric pneumococcal serotypes in elderly adults.

BACKGROUND Pneumococcal disease is most prevalent among young children and elderly adults. We explored whether similarities exist in the serotypes that cause disease in these 2 high-risk groups. METHODS With use of US population-based data from 1998-1999 (before the introduction of the 7-valent pneumococcal conjugate vaccine [PCV7] as routine immunization for infants) from the Centers for Disease Control and Prevention's Active Bacterial Core surveillance, we evaluated whether the rate of invasive pneumococcal disease caused by the pediatric serotypes (6B, 9V, 14, 19F, and 23F) increased among elderly persons. We adjusted for potential confounders in multivariable logistic regression. RESULTS We analyzed 2987 pneumococcal isolates recovered from adults. The risk of infection with pediatric serotypes increased from 32.5% in 35-49-year-old persons to 51.2% in > or = 85-year-old persons (P < .001). Compared with 35-49-year-old persons, the risk of infection with pediatric serotypes was significantly elevated among 65-74-year-old persons (relative risk [RR], 1.68; 95% confidence interval [CI], 1.29-2.20) and increased progressively among persons aged 75-84 years (RR, 1.82; 95% CI, 1.41-2.36) and > or = 85 years (RR, 2.29; 95% CI, 1.72-3.05), with adjustment for sex, race, geographic location, underlying illness, and penicillin resistance. The rate of penicillin resistance was also elevated in the elderly population but was not significant after adjustment for serotype and race. CONCLUSIONS The increased proportion of severe pneumococcal disease caused by pediatric serotypes in the elderly population might indicate opportunities for prevention with use of PCV7.

[1]  S. Madhi,et al.  Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. , 2004, The Journal of infectious diseases.

[2]  R. de Groot,et al.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease. , 2004, The Lancet. Infectious diseases.

[3]  H. Campbell,et al.  Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Schuchat,et al.  Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States. , 2003, The Journal of infectious diseases.

[5]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[6]  D. Feikin,et al.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[8]  G. Siber,et al.  Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children , 2001, The Lancet.

[9]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[10]  A. Schuchat,et al.  Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. , 2000, Archives of internal medicine.

[11]  M. Brisson,et al.  Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996–1998 , 2000, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[12]  N. French,et al.  23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial , 2000, The Lancet.

[13]  M. Kolczak,et al.  Cigarette smoking and invasive pneumococcal disease , 2000 .

[14]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[15]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Eskola,et al.  IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. , 1999, Vaccine.

[17]  D. Musher,et al.  IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Lampiris,et al.  Streptococcus pneumoniae Transmission in Chronic-Care Facilities: Description of an Outbreak and Review of Management Strategies , 1998, Infection Control &#x0026; Hospital Epidemiology.

[19]  M. Cetron,et al.  Outbreak of Pneumonia in a Long‐term Care Facility: Antecedent Human Parainfluenza Virus 1 Infection May Predispose to Bacterial Pneumonia , 1998, Journal of the American Geriatrics Society.

[20]  J. Butler,et al.  An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. , 1998, The New England journal of medicine.

[21]  B. Cookson,et al.  Pneumococci causing invasive disease in Britain 1982-1990. , 1998, Journal of medical microbiology.

[22]  K. Klugman,et al.  Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Steiner,et al.  Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. , 1997, JAMA.

[24]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[25]  M. Pichichero,et al.  Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults , 1997, Infection and immunity.

[26]  A J Hall,et al.  Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  K. Lottenbach,et al.  Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. , 1996, The Journal of infectious diseases.

[28]  M. Steinhoff,et al.  Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. , 1996, The Journal of infectious diseases.

[29]  D. Deegan.  Prevention of pneumococcal disease. , 1996, World of Irish nursing.

[30]  J. Hedlund,et al.  Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Hughes,et al.  Trends in antimicrobial drug prescribing among office-based physicians in the United States. , 1995, JAMA.

[32]  J. Kobayashi,et al.  Underutilization of pneumococcal vaccine in nursing home in Washington State: report of a serotype-specific outbreak and a survey. , 1993, The American journal of medicine.